Viral respiratory infection

26 submissions selected from a total of 281 applications from 47 countries to diagnose infectious and vector-borne diseases Awardees representing 12 countries in Europe, the Americas, Asia and Africa, will receive research grants of up to USD 600,000 per project As part of the Seegene's technology-sharing initiative, SG OneSystem Business™ aims to promote participation from the global scientific community, laying the groundwork to 'realize a world free from all diseases' SEOUL, South Korea, March 15, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, and Springer Nature, a world-leading provider of services to the research community, unveiled the final list of participants for the diagnostic reagent development project on March 15, 2024(GMT), through the online platform of the Open Innovation Program (). Continue Reading Seegene and Springer Nature Announce Awardees for the Open Innovation Program In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program. During the initial stage of document screening, a total of 281 applications were submitted from 47 different countries, demonstrating worldwide interest in the program. Two rounds of evaluations, which included document assessment and on-site evaluations specific to each country were conducted. Following the rigorous assessment process, a total of 26 applications were selected. The total number of selected awardees is 17, including those who applied for more than one project. Selected designated projects and the final number of awardees are as follows: Urinary Tract Infection (UTI): 3 projects, 9 awardees Dermatophyte: 1 project, 3 awardees Sexually Transmitted Infections (STI): 1 project, 2 awardees Vaginitis Screening: 1 project, 1 awardee Respiratory Panel (viral and bacterial respiratory infections): 2 projects, 2 awardees Nontuberculous Mycobacteria Typing: 1 project, 2 awardees Tick-borne Diseases: 1 project, 1 awardee Tropical Fever Virus (mosquito-borne tropical fever viruses): 1 project, 2 awardees Methicillin-resistant Staphylococcus aureus (MRSA): 1 project, 3 awardees Multidrug-resistant Organisms: 1 project, 1 awardee The Open Innovation Program resulted in awardees from a total of 12 countries with the following distribution: Belgium (3), the Netherlands (1), Germany (2), Italy (3), Portugal (1), Canada (3), the United States (3), Mexico (2), Argentina (1), UAE (3), South Korea (3), and Kenya (1). (Figures in parenthesis denote the number of projects selected) The awardees will receive research grants of up to USD 600,000 per project. Furthermore, Seegene will provide syndromic qPCR reagents, extraction reagents, development system (SGDDS), test instrument (AIOS), and related software free of charge throughout the collaboration period. Developing products that encapsulate the knowledge and experience of scientists from around the globe is essential to achieve the overarching vision: 'A World Free from All Diseases.' The inaugural Open Innovation Program marks the initial step in this endeavor. "Attracting numerous exceptional applicants from diverse backgrounds, the evaluations present an invaluable opportunity to cultivate a robust global network of clinical trial collaborations." said Dr. Jik Young Park, Head of Seegene's Development Automation. Dr. Park served as a member of the panel responsible for reviewing the submitted applications. The Open Innovation Program forms an integral part of Seegene's broader technology-sharing initiative, the SG OneSystem Business™ which debuted in 2023 and aligns with the company's vision of realizing a "world free from all diseases." The SG OneSystem Business™ involves the dissemination of Seegene's extensive expertise and knowledge accumulated over 20 years. The initiative includes collaborating with representative institutions from each country, to effectively develop diagnostic products tailored to meet the needs of the local market. In pursuit of this vision, Seegene has further bolstered its SG OneSystem Business™ through the strategic collaboration with Microsoft in January 2024, marking a significant milestone in its commitment to advancing global healthcare solutions. Seegene's Digitalized Development System (SGDDS), which enables less experienced researchers to develop assays, will integrate Microsoft Azure services, including Azure OpenAI Service. About Seegene Seegene has 23 years of dedicated R&D, manufacturing and business experience around syndromic quantitative PCR technologies, which was highlighted during the COVID-19 pandemic when it provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's unique syndromic PCR technologies is the ability to simultaneously test 14 pathogens that cause similar symptoms in a single tube and provide quantitative information on the infectivity profile to correlate with the severity of illness. SOURCE Seegene Inc.

First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections. Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data. The multi-center clinical trial in India will be a randomized double-blind placebo-controlled trial and is set to enroll 40 patients. ProLectin-M has previously established efficacy in two, previously conducted, peer-reviewed clinical trials with a 100% responders rate in both trials and p-values of .05 and .001. In the past decade only one other antiviral has, to our knowledge, achieved a similar preliminary efficacy profile. The Company has already established the non-toxic pro its galectin antagonists. Official additional studies are anticipated and planned in the United States. “After we complete the dose optimization trial, the next regulatory milestone is a registrational trial,” said Dr. Leslie Ajayi, Bioxytran’s medical director. “We are on the cusp of completing a clinical trial of standard risk patient that contracted COVID-19. Completing our registrational trial will position our oral galectin antagonist as the first line therapy for the single largest respiratory viral disease indication in the world. Should we achieve approval in COVID-19, we will embark on an expansion plan that will include influenza and Respiratory Syncytial Virus (RSV). We have reason to believe that our galectin antagonist is a broad spectrum antiviral capable of neutralizing a number of viruses capable of upper respiratory tract infections. We are advancing the field of Glycovirology and working toward bringing to market the potential first broad spectrum antiviral capable of neutralizing a number of viruses without changing the formulation and theoretically resistant to viral mutations.” “The discovery of a new binding region on the spike proteins of viruses has far reaching implications” said Kevin Mayo, Professor at the University of Minnesota, and also a member of Bioxytran’s scientific advisory board. “We used Nuclear Magnetic Resonance imaging to engineer / optimize a carbohydrate structure ideally suited to neutralize the spike protein of the SARS-CoV-2 virus. Before this discovery, neutralizing antibodies were only able to target the tip of the spike proteins of viruses which rapidly mutate, but after this discovery we found out that carbohydrates are able to neutralize viruses by binding to the galectin fold. The galectin fold represents a conserved structure on the spike protein virtually incapable of mutation, therefore it opens up a whole new field of research in Glycovirology. We believe a large number of viruses contain this galectin binding region on their spike proteins offering a widely druggable target that could be easily tested in a lab setting. With this discovery, we could use Nuclear Magnetic Resonance as a screening mechanism for viruses. In our COVID-19 case study we proved that the carbohydrate structures tested bound with high pico molar affinity, rarely seen with existing drugs, neutralize the viruses and that this data correlated with in vitro and the clinical trial results. We are at the dawn of a new age in virology that changes the current treatment paradigm of antivirals and vaccines to one of carbohydrate neutralization structures capable of efficiently neutralizing the virus to prevent cellular entry.” About ProLectin-M ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval. About Bioxytran, Inc. Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance spectroscopy fourier transformation mathematical process. The drug targets the galectin fold is a classical rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran’s molecules achieve virus neutralization. The extent of the carbohydrate structure’s ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at Investor Relations Michael Sheikh 509-991-0245 mike.sheikh@bioxytraninc.com Forward-Looking Statements This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

ROCKVILLE, Md., Feb. 12, 2024 /PRNewswire/ -- Trawsfynydd Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering antiviral treatments for respiratory viral diseases, today announced of a first-in-man clinical trial of the novel best-in-class COVID-19 treatment, TRX01, an inhibitor targeting the SARS-CoV-2 viral main protease (3CL, Mpro). "COVID-19 remains a significant global health concern, with SARS-CoV-2 infections posing a leading cause of mortality in the United States, especially among individuals aged 65 and above," stated C. David Pauza, PhD, CSO of Trawsfynydd Therapeutics. TRX01 was rationally designed as a best-in-class therapeutic, that does not require ritonavir co-administration, and represents a major advance in the field. "We are thrilled to proceed with clinical development of this novel COVID-19 therapy, which may increase the options for treating this deadly viral disease," Dr. Pauza added. The Phase 1 clinical trial marks the first assessment of human safety, tolerability, and pharmacokinetics for TRX01. About Trawsfynydd Therapeutics, Inc. Trawsfynydd Therapeutics, a biopharmaceutical company co-founded by Orbimed Advisors and Torrey Pines Investment, focuses on the discovery and development of best-in-class antiviral treatments for respiratory viral diseases. The company is utilizing a hybrid AI platform (Expert Systems Inc.) that leverages proprietary data of key partners, chem-bio platforms, knowledge, and expertise to choose highly valuable molecular mechanisms of pathology for precision design and to accelerate the execution of discovery and development of best-in-class and first-in-class therapies. The company's team of seasoned drug developers are using their capabilities and platforms to become a leader in developing novel breakthrough medicines that maximize the clinical benefit of treatments for respiratory viral diseases. Ongoing programs in Trawsfynydd are advancing clinical-stage assets for SARS-CoV-2 and influenza viral diseases. For more information, please visit . Media Contact: C. David Pauza, PhD Chief Science Officer [email protected] SOURCE Trawsfynydd Therapeutics